Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Epidermolysis Bullosa

Interventions

DRUG

allo-APZ2-OTS

Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

DRUG

Placebo

Trial Locations (1)

RECRUITING

EB-Haus Austria; Salzburger Landeskliniken (SALK), Salzburg

All Listed Sponsors

lead

RHEACELL GmbH & Co. KG

INDUSTRY